With global economies struggling it only gives drug manufacturers with sizable investment dollars more leverage to pit local and national governments against each other to see who can offer up the sweetest packages to earn the right to that money. GSK is playing tough with the UK over how it will invest going forward, demanding better tax incentives, patent support, etc. If not, GSK's Andrew Witty hints that Ireland, Belgium, Singapore and other locales are only more than happy to oblige. Pharmalot's Ed Silerman reports.
--Paul Thomas
